Victor Chun Kong Yu

Victor Chun Kong Yu

Auto-generated profile, based on publicly available information

Victor Chun Kong Yu

Department of Pharmacy, National University of Singapore, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1991 in Cell
Verified
Journal Article
Closed access
VYVictor C. Yu
Victor C. Yu
CDClaude Delsert
Claude Delsert
BABogi Andersen
Bogi Andersen
JHJeffrey M. Holloway
Jeffrey M. Holloway
ODOrly V. Devary
Orly V. Devary
MRMichael G. Rosenfeld
Michael G. Rosenfeld

1 June 1991 in Cell
Verified
Journal Article
Closed access
ANAnders M. Näär
Anders M. Näär
JBJean-Marle Boutin
Jean-Marle Boutin
SLSteven M. Lipkin
Steven M. Lipkin
VYVictor C. Yu
Victor C. Yu
JHJeffrey M. Holloway
Jeffrey M. Holloway
MRMichael G. Rosenfeld
Michael G. Rosenfeld

23 November 2003 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
BCBoon Tin Chua
Boon Tin Chua
CVChristiane Volbracht
Christiane Volbracht
KTKuan O. Tan
Kuan O. Tan
RLRong Li
Rong Li
VYVictor C. Yu
Victor C. Yu
PLPeng Li
Peng Li

1 June 2005 in Molecular Cell
Verified
Journal Article
Closed access
SBShairaz Baksh
Shairaz Baksh
STStella Tommasi
Stella Tommasi
SFSarah Fenton
Sarah Fenton
VYVictor C. Yu
Victor C. Yu
LMLuís Miguel Martins
Luís Miguel Martins
BNBenjamin G. Neel
Benjamin G. Neel

1 June 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SCShing-Leng Chan
Shing-Leng Chan
MLMei Chin Lee
Mei Chin Lee
KTKuan O. Tan
Kuan O. Tan
LYLay-Kien Yang
Lay-Kien Yang
ALAlex S. Y. Lee
Alex S. Y. Lee
VYVictor C. Yu
Victor C. Yu
The identification of small molecule inhibitors of antiapoptotic Bcl-2 family members has opened up new therapeutic opportunities, while the vast diversity of chemical structures and biological activities of natural products are yet to be systematically exploited. Here we report the identification of chelerythrine as an inhibitor of BclXL-Bak Bcl-2 homology 3 (BH3) domain binding through a high throughput screening of 107,423 extracts derived from natural products. Chelerythrine inhibited the BclXL-Bak BH3 peptide binding with IC50 of 1.5 μm and displaced Bax, a BH3-containing protein, from BclXL. Mammalian cells treated with chelerythrine underwent apoptosis with characteristic features that suggest involvement of the mitochondrial pathway. While staurosporine, H7, etoposide, and chelerythrine released cytochrome c from mitochondria in intact cells, only chelerythrine released cytochrome c from isolated mitochondria. Furthermore BclXL-overexpressing cells that were completely resistant to apoptotic stimuli used in this study remained sensitive to chelerythrine. Although chelerythrine is widely known as a protein kinase C inhibitor, the mechanism by which it mediates apoptosis remain controversial. Our data suggest that chelerythrine triggers apoptosis through a mechanism that involves direct targeting of Bcl-2 family proteins.

19 February 2004 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Open access
PDF file
SCShing‐Leng Chan
Shing‐Leng Chan
VYVictor C Yu
Victor C Yu
SUMMARY: 1. Proteins of the Bcl‐2 family are central regulators of apoptosis and are thought to act primarily on the mitochondria.2. Members of the Bcl‐2 family possess either anti‐apoptotic or pro‐apoptotic function. They are characterized by the presence of conserved sequence motifs, known as Bcl‐2 homology (BH) domains. Anti‐apoptotic members share all four BH domains, designated as BH1‐4; the multidomain pro‐apoptotic members contain BH1‐3 domains, whereas another subgroup of pro‐apoptotic members only have a BH3 domain.3. The BH3‐only proteins act as sensors for distinct apoptosis pathways, whereas multidomain pro‐apoptotic Bax and Bak are executioners of death orders relayed by the BH3‐only proteins.4. Anti‐apoptotic Bcl‐2 family members appear to function, at least in part, by interacting with and antagonizing pro‐apoptotic family members. The BH1‐3 domains of BclXL form an elongated hydrophobic groove, which is the docking site for the BH3 domains of pro‐apoptotic binding partners.5. The deregulation of the various Bcl‐2 proteins has been implicated in many pathological conditions.6. Knowledge derived from the understanding of the function and regulation of the Bcl‐2 family of proteins has allowed us to contemplate new therapeutic strategies for diseases where apoptosis signalling mechanisms can potentially be manipulated.7. The anti‐apoptotic Bcl‐2 members have been targeted successfully using an antisense approach, BH3‐peptides and small molecular weight chemicals that are inhibitors of their anti‐apoptotic function.